THE US FDA has approved
Tudorza Pressair (aclidinium bromide)
for the long-term maintenance
treatment of bronchospasm
(narrowing of the airways in the
lung) associated with chronic
obstructive pulmonary disease,
including chronic bronchitis and
emphysema.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 31 Jul 12 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 12
THE Australian Competition and Consumer Commission (ACCC) has given the green light to the proposed merger of Arrow and Apotex (PD 10 May 2018), finding that the transaction “will not substantially lessen competition in any market”.
NEGOTIATIONS between the Pharmacy Guild of Australia and the Health Department have seen the release of amendments to the Pharmacy Location Rules (PD breaking news), with Health Minister Greg Hunt signing an Amending Determination this week to enact the new arrangements.